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Abstract
BACKGROUND: Aim of this study was to determine the value of technetium-99m-hydrazinonicotinyl-Tyr3-octreotide (99mTc-EDDA/ 
/HYNIC-TOC) in patients with somatostatin receptor (SSR) positive tumors of head and neck region.
MATERIAL AND METHODS: A total number of 16 patients were enrolled in this study. Planar whole body (WB) and single 
photon emission computed tomography (SPECT) images were acquired at 2 and 4 hours after the injection of approximately 
670 MBq of 99mTc-EDDA/HYNIC-TOC. Additional single photon emission computed tomography/computed tomography 
(SPECT/CT) images of the head and neck region were acquired at 4h post tracer injection. Clinical and imaging follow up 
were taken as the reference standard.
RESULTS: There were 10 female and 6 male patients of age 57.7 ± 12.9 years (58.5; 32–78) years. 99mTc-EDDA/HYNIC-TOC 
somatostatin receptor scintigraphy (SRS) was TP in 13 patients, TN in two and FP in one. Follow up period for SRS was 31.1 ± 
19.4 (29; 2–63) months. 99mTc-EDDA/HYNIC-TOC scintigraphy provided additional information in 50% of patients, with impact 
on patient management in the same percentage of patients. Distant metastases were found in nine out of 16 patients (56%). 
99mTc-EDDA/HYNIC-TOC SRS had sensitivity of 100% (75.3–100%), specificity of 66.7% (9.4–99.2%), accuracy of 93.7%, posi-
tive predictive value of 92.9% (66.1–99.8%), and negative predictive value of 100% (15.8–100%).
CONCLUSION: Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC is very useful imaging method in the evalu-
ation of patients with SSR positive tumors of head and neck region.
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Background
Somatostatin receptor scintigraphy (SRS) is considered 
as an imaging modality of choice for many neuroendocrine tu-
mors (NETs). NETs of head and neck are rare group of neoplasms. 
NETs originate from neural crest cells and have both neural and 
endocrine cell features [1]. Head and neck NETs can be divided in 
two groups: epithelial derived tumors (typical carcinoid, atypical car-
cinoid and small cell carcinoma) and neurally derived tumors (para-
ganglioma, olfactory neuroblastoma) [2]. Rarely, NETs from other 
sites can also metastasize to the head and neck region [3]. Some 
other types of head and neck tumors; medullary thyroid carcinoma 
(MTC), meningioma, Hurthle cell carcinoma, also showed somato-
statin receptors (SSRs) on the cell membrane surface [4].
SRS is indicated in the staging of SSR overexpressing tu-
mors, restaging, detection of eligibility for “cold” somatostatin 
analogues (SSAs) or somatostatin receptors directed radionuclide 
therapy (peptide radionuclide receptor therapy — PRRT). SRS 
is useful in monitoring response to “cold” SSAs and in detection 
of primary SSR positive tumors [5, 6]. 
The radiopharmaceutical 111Indium-octreotide (OctreoScan™, 
Mallinckrodt, Petten, Netherlands) has been considered as the 
gold standard for the management of NET patients [7–9]. Tech-
netium-99m (99mTc) labeled hydrazinonicotinyl-Tyr3-octreotide 
(EDDA/HYNIC-TOC, Tektrotyd) has advantages of short half-life, 
lower radiation burden; so higher dosage can be administered 
producing better image quality. Physical characteristics of 99mTc 
are more suited for gamma cameras and single photon emission 
computed tomography (SPECT) imaging [10–12]. 99mTc labeled 
EDDA/HYNIC-TOC is also a good alternative to Gallium-68 radio-
tracers (labeled peptides: DOTA-TOC, DOTA-NOC, DOTA-TATE) 
where PET/CT or Gallium-68 generators are not available.
MTC is a rare malignancy and in comparison with other types of 
thyroid carcinoma, MTC is more demanding and more difficult 
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to treat with higher rates of recurrence and mortality. Different 
radiopharmaceuticals are used for detection of occult metastatic 
disease and SRS with 99mTc-EDDA/HYNIC-TOC is the promising 
method [13–15].
The aim of this study was to determine the value of 99mTc 
EDDA/HYNIC-TOC in patients with neuroendocrine and other SSR 
positive tumors of head and neck region in terms of sensitivity, 
specificity, diagnostic accuracy. Impact on patient management 
was also evaluated.
Material and methods
Patients, radiopharmaceutical and imaging
All patients gave their written informed consent for the study. 
This is a retrospective study of 16 patients who referred to our 
Department for a routine examination between February 2011 
and March 2016. 99mTc-EDDA/HYNIC-TOC was prepared from 
a commercially available kit (Tektrotyd, Polatom, Otwock, Poland) 
following the manufacturer’s instructions. Patients were intrave-
nously injected with an average activity of 670 MBq of the tracer. 
Imaging was performed at 2 and 4 hours with a double-headed 
gamma camera (Symbia T; Siemens Medical Solutions, Erlangen, 
Germany). Planar whole body (WB) and single photon emission 
computed tomography (SPECT) images were acquired at 2 and 
4 h. Single photon emission computed tomography/computed 
tomography (SPECT/CT) images of the head and neck region, or 
other region of interest, were acquired at 4 h. SPECT image data 
were reconstructed using FLASH-3D iterative reconstruction with 
8 iterations and 8 subsets [16]. All images were reconstructed using 
syngoMI workstation (SynogMI VA60B; Siemens Medical Solution, 
Erlangen, Germany).
Any focal tracer accumulation exceeding normal regional tracer 
uptake was rated as a pathologic tumor uptake. Image analy-
sis was done visually by experienced nuclear medicine physician 
who performed more than 200 99mTc-EDDA/HYNIC-TOC SPECT/CT 
studies in the past four years.
Quantitative data are presented as their mean ± standard 
deviation (median; range), if not otherwise stated. Findings on 
SRS images were classified as true-positive (TP), true-negative 
(TN), false-positive (FP), or false-negative (FN), as compared to 
the reference standard (conventional imaging methods, clinical 
and biochemical follow up). 
Results
Patient characteristics are detailed in Table 1. There were 10 
female and 6 male patients of age 57.7 ± 12.9 years, (58.5; 32–78) 
years. Details of the findings of 99mTc-EDDA/HYNIC-TOC images are 
presented in Table 2. 99mTc-EDDA/HYNIC-TOC images were inter-
preted as positive in 14 patients and as negative in two patients. 
Follow up period for SRS was 31.1 ± 19.4 (29; 2–63) months. 
99mTc-EDDA/HYNIC-TOC SPECT/CT was TP in 13 patients, TN in 
two and FP in one. Representative cases are shown in Figures 1–6.
In cases number 1, 2, 6 and 16 SRS was performed for staging 
of the disease. In cases number 2 and 16, as both patients had 
NEC of unknown primary (CUP), location of primary tumor was in 
main focus together with correct staging of the disease. In all 
other cases (3–5, 7–15) SRS was performed for restaging of the 
disease.
Cases number 13 and 15, both MTC, were TN with fairly 
long follow up period of 45 and 53 months, respectively. During 
this follow up numerous imaging techniques were performed in 
both patients including whole body PET/CT, MSCT (of the neck, 
thorax and abdomen region) and once per year US examination 
of the neck. Once in a year during follow up period patients were 
admitted to the hospital and on each occasion one of mentioned 
imaging modality (PET/CT or MSCT) was performed together with 
US of the neck region.
Table 1. Patient and tumor characteristics
Patient Number Sex Age (years) Follow up (months) Primary tumor site Pathohistology WHO Classification
1 M 52 29 Pharynx NEC G3
2 F 43 2 CUP NEC G3
3 F 78 38 Lacrimal gland NET G2
4 F 65 28 Thyroid MTC n/a
5 M 61 4 Pharynx NEC G3
6 F 42 12 Lacrimal gland NET G2
7 M 69 63 Larynx NEC G3
8 F 32 41 Meninges Meningioma G3
9 F 73 28 Thyroid Hurthle cell n/a
10 F 67 6 Thyroid MTC n/a
11 M 71 15 Thyroid MTC n/a
12 F 53 45 Thyroid MTC n/a
13 F 52 45 Thyroid MTC n/a
14 F 56 59 Thyroid MTC n/a
15 M 45 53 Thyroid MTC n/a
16 M 64 29 CUP NEC G3
M — male; F — female; CUP — cancer of unknown primary; NEC — neuroendocrine cancer; NET — neuroendocrine tumor; MTC — medullary thyroid cancer; G2 — grade 2; G3 — grade 3; 
n/a — not applicable
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imaging methods. In all this cases “cold” SSAs were introduced. 
In two additional patients (cases 2 and 16) “cold” SSAs were also 
introduced after positive scintigraphy. Treatment of one patient 
(case 14) was changed to PRRT after positive scintigraphy scan. 
In overall, on a clinical basis 99mTc-EDDA/HYNIC-TOC scintigraphy 
provided additional information in 50% of patients, with impact on 
patient management in the same percentage of patients. Distant 
metastases were found in 56% of patients (9/16). Metastatic bone 
disease was the most common site of distant metastases in 31% 
of patients (5/16). Other sites were lymph nodes in 25% (4/16), 
lungs in 12% (2/16), brain in 6% (1/16) and liver in also 6% (1/16). 
In one patient (case 3) direct extension of tumor from eyelid and 
orbital cavity to sphenoid bone was seen. In this patient FP result 
(in terms of NET spread) was seen in both parotid glands due to 
chronic inflammatory changes of salivary glands (Sjogren’s syn-
drome, Figure 4).
In group of patients with NEC (patients 1, 2, 5, 7 and 16) PET/CT 
and US were used in all patients as reference imaging modality 
for follow up, while in patients 1, 2 and 5 (because of the neck or 
head and neck involvement) additional MRI of the head and/or neck 
was performed. No difference between imaging modalities (99mTc 
EDDA/HYNIC-TOC vs. 18F-FDG PET/CT or MRI) was noted. In group 
of NEC distant metastasis were found in 60% of the patients (3/5).
The comparison between 99mTc-EDDA/HYNIC-TOC SRS and 
reference standard (conventional imaging methods, clinical and 
biochemical follow up) showed that SRS had sensitivity of 100% 
(75.3%–100%), specificity of 66.7% (9.4%–99.2%), accuracy of 
93.7%, positive predictive value of 92.9% (66.1%–99.8%), and 
negative predictive value of 100% (15.8%–100%).






Lesions locations Distant 
metastasis
1 Yes Nasopharynx, Base of skull, 
NLN (M)
No
2 Yes Brain (M), ALN (M) Yes
3 Yes Orbital cavity, Bone (Sphenoid) No
4 Yes Bone (sacrum) Yes
5 Yes Laryngopharynx, NLN (M) No
6 Yes Orbital cavity No
7 Yes Bone (M) Yes
8 Yes Brain No
9 Yes Lungs (M) Yes
10 Yes Bone (M) Yes
11 Yes Bone (humerus), Lungs (M) Yes
12 Yes Liver Yes
13 No 0 No
14 Yes Bone (M) Yes
15 No 0 No
16 Yes NLN(M) Yes
M — multiple lesions; 0 — no lesions; NLN — neck lymph nodes; ALN — abdominal lymph 
nodes
Figure 1. A 65-year-old female with medullary thyroid carcinoma (case number 4). 99mTc-EDDA/HYNIC-TOC SPECT/CT revealed distant metastasis 
in sacrum. SPECT/CT, single photon emission computed tomography/computed tomography
In five patients (cases 4, 7, 10, 11 and 14) distant spread of 
disease to skeletal system was found. In these cases 99mTc-EDDA/ 
/HYNIC-TOC findings upstaged disease to stage IV (distant 
metastasis). This changed initial staging done by conventional 
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Discussion
Precise diagnosis and staging are of incremental value in direct-
ing therapy for tumors of head and neck region. Surgical resection 
is still first choice treatment for a patients with head and neck 
malignancies, including NET, MTC and other types of SSR posi-
tive tumors. In a metastatic disease multiple options are available. 
In patients with positive finding on SRS one of these options are 
“cold” SSAs. SSAs are used to control hormone related symptoms. 
Patients using SSA showed symptomatic and biochemical improve-
ment. SSA anti-tumor effects are still under investigation, they have 
direct impact on proliferative signaling pathways, on activation of 
apoptosis, on angiogenesis and on tumor stabilization [17, 18]. 
In a subgroup of MTC, 99mTc-EDDA/HYNIC-TOC SRS showed 
incremental value in identifying additional metastatic lesions, espe-
cially distant metastatic lesions in skeletal system, providing more 
Figure 2. A 61-year-old male with NEC of laryngopharynx (case number 5). 99mTc-EDDA/HYNIC-TOC SPECT/CT showed intensive uptake in neck 
lymph nodes (bilateral) and in primary tumor of laryngopharynx. NEC, neuroendocrine carcinoma; SPECT/CT, single photon emission computed 
tomography/computed tomography
Figure 3. A 42-year-old female with NET G2 (Ki67 8%) of lacrimal gland (case number 6). 99mTc-EDDA/HYNIC-TOC SPECT/CT was done as 
preoperative staging. SPECT/CT (axial, sagittal and coronal view) showed increased radiopharmaceutical uptake in the right orbital cavity. NET G2, 
neuroendocrine tumor grade 2; SPECT/CT, single photon emission computed tomography/computed tomography
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accurate staging in these patients. In our group 31% (5/16) of pa-
tients were upstaged by SRS, four of them were MTC. Czep czynski 
et al. showed clinical usefulness of 99mTc-EDDA/HYNIC-TOC in fol-
low up of patients with medullary thyroid carcinoma. 99mTc-EDDA/ 
/HYNIC-TOC had sensitivity of 79.5%, specificity of 83.3% and 
diagnostic accuracy of 80% [15].
Although Hurthle cell carcinomas do not belong to the tradi-
tional group of NETs, positive SSR in these tumors could provide, 
especially in negative radioiodine cases, new treatment option like 
PRRT [4, 19, 20].
Somatostatin scintigraphy of receptors type 2 with radiolabeled 
octreotide has been shown to be very useful in the meningioma 
diagnosis [21–23]. In their published study Wang et al. showed that 
99mTc-HYNIC-octreotide SPECT/CT SRS is a sensitive method for de-
tecting meningioma [24]. Several authors investigated this topic us-
ing 68Ga-DOTA-peptides PET/CT [25]. We had only one patient with 
meningioma and 99mTc-EDDA/HYNIC-TOC SPECT/CT in this case 
provided additional information concerning tumor recurrence 
and extension. Planned radiotherapy target volume was slightly 
modified based on SPECT/CT data. Improved treatment planning 
Figure 4. A 78-year-old female with NET G2 of lacrimal gland (case number 3). 99mTc-EDDA/HYNIC-TOC SPECT/CT was done as 
restaging. SPECT/CT images (axial view) revealed intensive uptake in left orbital cavity. SPECT/CT showed as well intensive uptake of the 
radiopharmaceutical in both parotid glands — Sjogren’s syndrome. NET G2, neuroendocrine tumor grade 2; SPECT/CT, single photon emission 
computed tomography/computed tomography
Figure 5. A 43-year-old female with neuroendocrine carcinoma of unknown primary site (case number 2). 99mTc-EDDA/HYNIC-TOC SPECT/CT 
didn’t reveal primary tumor site. SPECT/CT (axial view) showed increased radiopharmaceutical uptake in frontal and parietal lobe. SPECT/CT, 
single photon emission computed tomography/computed tomography
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for meningioma using 68Ga-DOTATOC PET/CT is more and more 
available method [26–28]. Usefulness of 99mTc-EDDA/HYNIC-TOC 
SPECT/CT in this indication is still to be investigated.
“Cold” SSAs were introduced in cases number 2, 4, 7, 10, 
11, 14 and 16. In cases number 2 (CUP NEC) and 16 (CUP NEC) 
“cold” SSAs were introduced to reduce the number of flushing 
episodes and to improve general clinical condition of patients. 
Good clinical response to the treatment with reduced number of 
flushing episodes was noticed after introduction of long-acting SSA.
In five other cases (four MTC and one NEC of larynx), based on 
positive expression of somatostatin receptors, “cold” SSAs were 
introduced as antineoplastic treatment but no beneficial effect 
and no significant improvement in the natural course of the tumor 
was noted. More evident was an improvement in clinical symp-
toms as general weakness and weight loss in all the patients. Cur-
rently, randomized control studies referring on antitumor effect in 
patients with MTC, do not exist and only case series or studies of 
limited value are published, which were not able to demonstrate 
any consistent antitumor somatostatin effect [29–32].
According to Clarinet study (Controlled Study of Lanreotide 
Antiproliferative Response in Neuroendocrine Tumors), usage 
of long-acting SSA was associated with significantly prolonged 
progression-free survival among patients with metastatic enteropan-
creatic neuroendocrine tumors of grade 1 or 2 (Ki-67 < 10%) [33, 34]. 
This positive antineoplastic result was not seen in our very small group 
of patients with MTC and NEC (n = 7) that received “cold” SSA.
There are a number of limitations in this study; retrospective 
design, sample size was small, group consisted of patients with het-
erogeneous population of different SSR positive primary tumors (NET, 
MTC, meningioma, Hurthle cell carcinoma and unknown primary 
NET tumor with metastases in head and neck region in two patients). 
In our subgroup of NETs only grade 2 and grade 3 NETs were present, 
we didn’t have well-differentiated (low grade) NETs and this could 
have significantly impact study results. Stu dies investigating larger 
and more homogeneous populations are needed.
Conclusion
99mTc-EDDA/HYNIC-TOC SRS shows high accuracy in detecting 
SSR positive tumors. SRS is an excellent imaging modality and reli-
able tool in the evaluation and treatment planning of patients with 
SSR positive tumors of head and neck region.
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